<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02094716</url>
  </required_header>
  <id_info>
    <org_study_id>185-7851-201</org_study_id>
    <nct_id>NCT02094716</nct_id>
  </id_info>
  <brief_title>A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel Group Comparison Study of the Safety and Efficacy of Permethrin Foam, 5% Versus Permethrin Foam, 4% Versus Vehicle in Subjects With Sarcoptes Scabiei</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DPT Laboratories, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vyne Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine and compare the safety and efficacy of permethrin foam 4% and permethrin foam 5%&#xD;
      with that of vehicle in subjects with scabies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is anticipated that a majority of subjects will require and receive a single treatment;&#xD;
      however, those subjects not showing improvement at the follow-up visit 2 weeks after initial&#xD;
      treatment will be treated a second time. Those subjects originally assigned to vehicle for&#xD;
      the first treatment will receive a &quot;re-treatment&quot; with one of the active doses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Who Received a Single Treatment of the Assigned Test Article That Were Designated as &quot;Treatment Success&quot;</measure>
    <time_frame>Day 28</time_frame>
    <description>The primary efficacy variable is &quot;treatment success&quot;. In protocol v2.0, &quot;treatment success&quot; was defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear). In protocol v3.0, &quot;treatment success&quot; was defined as an &quot;eradication of infestation&quot;: a) no burrows, b) a reduction in the Signs/Symptoms, and c) no evidence of a live mite on microscopy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Disease-related Signs and Symptoms for Those Subjects Provided With Re-treatment at Day 14 Who Show Improvement in Their Investigator's Global Assessment (IGA) Score at Day 28</measure>
    <time_frame>Baseline, Day 14, 28, and 42</time_frame>
    <description>The change in the total score of signs and symptoms related to the condition in each treatment group at Days 14 and 28, as well as at Day 42 for those subjects provided with re-treatment at Day 14 who show improvement in their IGA score at Day 28.&#xD;
Scale details: The overall average presence of the individual signs and symptoms of scabies was evaluated over the entire body. Erythema, papules, pustules, crusting, scaling, excoriations, and pruritus were assessed as follows for each sign and symptom: None=0, Trace=1, Mild=2, Moderate=3, Severe=4. From these assessments, the total score of the Signs and Symptoms (from 0 to 28, higher scores mean a worse outcome) was calculated as the sum of the individual signs and symptoms scores at Baseline and Days 2, 14, 28, and 42 (if applicable).The change from baseline in the total score can range from -28 as the best reduction possible (better outcome) to +28 as the worst increase possible (worse outcome) in signs and symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Re-treated Subjects Designated as &quot;Treatment Success&quot;</measure>
    <time_frame>Day 42</time_frame>
    <description>Each subject was designated as &quot;re-treatment success&quot; at Day 42 based upon the criteria in the protocol to which he/she was enrolled. In protocol v2.0, &quot;treatment success&quot; was defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear). In protocol v3.0, &quot;treatment success&quot; was defined as an &quot;eradication of infestation&quot;: a) no burrows, b) a reduction in the Signs/Symptoms, and c) no evidence of a live mite on microscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Designated as &quot;Treatment Success&quot; Following One Treatment With an Active Dose</measure>
    <time_frame>Day 28 and Day 42</time_frame>
    <description>The proportion of subjects designated as &quot;treatment success&quot; following one treatment versus two treatments.&#xD;
In protocol v2.0, &quot;treatment success&quot; was defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear). In protocol v3.0, &quot;treatment success&quot; was defined as an &quot;eradication of infestation&quot;: a) no burrows, b) a reduction in the Signs/Symptoms, and c) no evidence of a live mite on microscopy.&#xD;
Subjects originally assigned to vehicle treatment and re-treated on Day 14 with an active dose will be included with the single treatment group for this analysis.&#xD;
Subjects who did not improve at Day 14 were counted as failures at Day 28. Subjects who improved at Day 14 and received a second treatment in error were counted as failures at Day 28.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Scabies</condition>
  <arm_group>
    <arm_group_label>Permethrin Foam 4%/ Permethrin Foam 4%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First treatment with Permethrin Foam 4% with potential to re-treat with Permethrin Foam 4%, if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Permethrin Foam 5%/ Permethrin Foam 5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First treatment with Permethrin Foam 5% with potential to re-treat with Permethrin Foam 5%, if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Foam / Permethrin Foam 4%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>First treatment with Vehicle with potential to re-treat with Permethrin Foam 4%, if necessary.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle / Permethrin Foam 5%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>First treatment with Vehicle with potential to re-treat with Permethrin Foam 5%, if necessary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Permethrin Foam 4%</intervention_name>
    <description>Topical application, whole-body treatment</description>
    <arm_group_label>Permethrin Foam 4%/ Permethrin Foam 4%</arm_group_label>
    <arm_group_label>Vehicle Foam / Permethrin Foam 4%</arm_group_label>
    <other_name>PF-045</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Permethrin Foam 5%</intervention_name>
    <description>Topical application, whole-body treatment</description>
    <arm_group_label>Permethrin Foam 5%/ Permethrin Foam 5%</arm_group_label>
    <arm_group_label>Vehicle / Permethrin Foam 5%</arm_group_label>
    <other_name>PF-055</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Foam</intervention_name>
    <description>Topical application, whole-body treatment</description>
    <arm_group_label>Vehicle / Permethrin Foam 5%</arm_group_label>
    <arm_group_label>Vehicle Foam / Permethrin Foam 4%</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of active scabies infection.&#xD;
&#xD;
          -  Subject is in good general health with normal appearing skin in noninfested areas.&#xD;
&#xD;
          -  Females must be post-menopausal, surgically sterile or use an effective method of&#xD;
             birth control with a negative pregnancy test (10 years of age and older) at study&#xD;
             start.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is pregnant, lactating, or is planning to become pregnant during the study.&#xD;
&#xD;
          -  Subject has used any ectoparasiticide within the three weeks prior to study start.&#xD;
&#xD;
          -  Subject has signs of systemic infection or is receiving systemic therapy for an&#xD;
             infectious disease.&#xD;
&#xD;
          -  Subject has severe cutaneous bacterial or fungal infections requiring therapy or&#xD;
             heavily crusted lesions consistent with Norwegian scabies.&#xD;
&#xD;
          -  Subject is currently enrolled in an investigational drug or device study or has used&#xD;
             an investigational drug or device within 30 days prior to study start.&#xD;
&#xD;
          -  Subject whose close personal contacts will not comply with standard of care for fomite&#xD;
             management.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>San Crist√≥bal</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>San Pedro Sula</city>
        <country>Honduras</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
    <country>Honduras</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 20, 2014</study_first_submitted>
  <study_first_submitted_qc>March 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2014</study_first_posted>
  <results_first_submitted>August 19, 2020</results_first_submitted>
  <results_first_submitted_qc>December 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 15, 2021</results_first_posted>
  <disposition_first_submitted>August 3, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>August 3, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 8, 2017</disposition_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sarcoptes</keyword>
  <keyword>Scabiei</keyword>
  <keyword>Scabies</keyword>
  <keyword>ectoparasite</keyword>
  <keyword>parasite</keyword>
  <keyword>infestation</keyword>
  <keyword>Renaissance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scabies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Permethrin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Permethrin Foam 4%/ Permethrin Foam 4%</title>
          <description>First treatment with Permethrin Foam 4% with potential to re-treat with Permethrin Foam 4%, if necessary.&#xD;
Topical application, whole-body treatment</description>
        </group>
        <group group_id="P2">
          <title>Permethrin Foam 5%/ Permethrin Foam 5%</title>
          <description>First treatment with Permethrin Foam 5% with potential to re-treat with Permethrin Foam 5%, if necessary.&#xD;
Topical application, whole-body treatment</description>
        </group>
        <group group_id="P3">
          <title>Vehicle Foam</title>
          <description>First treatment with Vehicle with potential to re-treat with Permethrin Foam, if necessary.&#xD;
Topical application, whole-body treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Second Dose at Day 14</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Permethrin Foam 4%/ Permethrin Foam 4%</title>
          <description>First treatment with Permethrin Foam 4% with potential to re-treat with Permethrin Foam 4%, if necessary.&#xD;
Topical application, whole-body treatment</description>
        </group>
        <group group_id="B2">
          <title>Permethrin Foam 5%/ Permethrin Foam 5%</title>
          <description>First treatment with Permethrin Foam 5% with potential to re-treat with Permethrin Foam 5%, if necessary.&#xD;
Topical application, whole-body treatment</description>
        </group>
        <group group_id="B3">
          <title>Vehicle Foam</title>
          <description>First treatment with Vehicle with potential to re-treat with Permethrin Foam, if necessary.&#xD;
Topical application, whole-body treatment</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="44"/>
            <count group_id="B4" value="130"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.1" spread="20.8"/>
                    <measurement group_id="B2" value="23.4" spread="18.4"/>
                    <measurement group_id="B3" value="26.1" spread="20.4"/>
                    <measurement group_id="B4" value="25.9" spread="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Received a Single Treatment of the Assigned Test Article That Were Designated as &quot;Treatment Success&quot;</title>
        <description>The primary efficacy variable is &quot;treatment success&quot;. In protocol v2.0, &quot;treatment success&quot; was defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear). In protocol v3.0, &quot;treatment success&quot; was defined as an &quot;eradication of infestation&quot;: a) no burrows, b) a reduction in the Signs/Symptoms, and c) no evidence of a live mite on microscopy.</description>
        <time_frame>Day 28</time_frame>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Permethrin Foam 4%/ Permethrin Foam 4%</title>
            <description>First treatment with Permethrin Foam 4% with potential to re-treat with Permethrin Foam 4%, if necessary.&#xD;
Topical application, whole-body treatment</description>
          </group>
          <group group_id="O2">
            <title>Permethrin Foam 5%/ Permethrin Foam 5%</title>
            <description>First treatment with Permethrin Foam 5% with potential to re-treat with Permethrin Foam 5%, if necessary.&#xD;
Topical application, whole-body treatment</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Foam</title>
            <description>First treatment with Vehicle with potential to re-treat with Permethrin Foam, if necessary.&#xD;
Topical application, whole-body treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Received a Single Treatment of the Assigned Test Article That Were Designated as &quot;Treatment Success&quot;</title>
          <description>The primary efficacy variable is &quot;treatment success&quot;. In protocol v2.0, &quot;treatment success&quot; was defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear). In protocol v3.0, &quot;treatment success&quot; was defined as an &quot;eradication of infestation&quot;: a) no burrows, b) a reduction in the Signs/Symptoms, and c) no evidence of a live mite on microscopy.</description>
          <population>Intent to Treat (ITT)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6084</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Disease-related Signs and Symptoms for Those Subjects Provided With Re-treatment at Day 14 Who Show Improvement in Their Investigator's Global Assessment (IGA) Score at Day 28</title>
        <description>The change in the total score of signs and symptoms related to the condition in each treatment group at Days 14 and 28, as well as at Day 42 for those subjects provided with re-treatment at Day 14 who show improvement in their IGA score at Day 28.&#xD;
Scale details: The overall average presence of the individual signs and symptoms of scabies was evaluated over the entire body. Erythema, papules, pustules, crusting, scaling, excoriations, and pruritus were assessed as follows for each sign and symptom: None=0, Trace=1, Mild=2, Moderate=3, Severe=4. From these assessments, the total score of the Signs and Symptoms (from 0 to 28, higher scores mean a worse outcome) was calculated as the sum of the individual signs and symptoms scores at Baseline and Days 2, 14, 28, and 42 (if applicable).The change from baseline in the total score can range from -28 as the best reduction possible (better outcome) to +28 as the worst increase possible (worse outcome) in signs and symptoms.</description>
        <time_frame>Baseline, Day 14, 28, and 42</time_frame>
        <population>Missing data not included</population>
        <group_list>
          <group group_id="O1">
            <title>Permethrin Foam 4%; Permethrin Foam 4%</title>
            <description>First treatment with Permethrin Foam 4% with re-treatment with Permethrin Foam 4% at Day 14 who were also improving at Day 28.&#xD;
Topical application, whole-body treatment</description>
          </group>
          <group group_id="O2">
            <title>Permethrin Foam 5%; Permethrin Foam 5%</title>
            <description>First treatment with Permethrin Foam 5% with re-treatment with Permethrin Foam 5% at Day 14 who were also improving at Day 28.&#xD;
Topical application, whole-body treatment</description>
          </group>
          <group group_id="O3">
            <title>Vehicle; Permethrin Foam 4%</title>
            <description>First treatment with Vehicle Foam with second treatment with Permethrin Foam 4% at Day 14 who were also improving at Day 28&#xD;
Topical application, whole body treatment</description>
          </group>
          <group group_id="O4">
            <title>Vehicle Foam; Permethrin Foam 5%</title>
            <description>First treatment with Vehicle with second treatment of Permethrin Foam 5% at Day 14 who were also improving at Day 28.&#xD;
Topical application, whole-body treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Disease-related Signs and Symptoms for Those Subjects Provided With Re-treatment at Day 14 Who Show Improvement in Their Investigator's Global Assessment (IGA) Score at Day 28</title>
          <description>The change in the total score of signs and symptoms related to the condition in each treatment group at Days 14 and 28, as well as at Day 42 for those subjects provided with re-treatment at Day 14 who show improvement in their IGA score at Day 28.&#xD;
Scale details: The overall average presence of the individual signs and symptoms of scabies was evaluated over the entire body. Erythema, papules, pustules, crusting, scaling, excoriations, and pruritus were assessed as follows for each sign and symptom: None=0, Trace=1, Mild=2, Moderate=3, Severe=4. From these assessments, the total score of the Signs and Symptoms (from 0 to 28, higher scores mean a worse outcome) was calculated as the sum of the individual signs and symptoms scores at Baseline and Days 2, 14, 28, and 42 (if applicable).The change from baseline in the total score can range from -28 as the best reduction possible (better outcome) to +28 as the worst increase possible (worse outcome) in signs and symptoms.</description>
          <population>Missing data not included</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 14 Change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="2.7"/>
                    <measurement group_id="O2" value="0.6" spread="2.0"/>
                    <measurement group_id="O3" value="-0.1" spread="2.5"/>
                    <measurement group_id="O4" value="0.6" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 Change from Prior Visit (Day 14)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.2" spread="4.5"/>
                    <measurement group_id="O2" value="-9.0" spread="5.9"/>
                    <measurement group_id="O3" value="-11.4" spread="6.7"/>
                    <measurement group_id="O4" value="-9.7" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42 Change from Prior Visit (Day 28)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="4.0"/>
                    <measurement group_id="O2" value="-2.5" spread="2.9"/>
                    <measurement group_id="O3" value="-2.4" spread="2.4"/>
                    <measurement group_id="O4" value="-3.4" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Re-treated Subjects Designated as &quot;Treatment Success&quot;</title>
        <description>Each subject was designated as &quot;re-treatment success&quot; at Day 42 based upon the criteria in the protocol to which he/she was enrolled. In protocol v2.0, &quot;treatment success&quot; was defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear). In protocol v3.0, &quot;treatment success&quot; was defined as an &quot;eradication of infestation&quot;: a) no burrows, b) a reduction in the Signs/Symptoms, and c) no evidence of a live mite on microscopy.</description>
        <time_frame>Day 42</time_frame>
        <population>ITT subjects who did not improve at Day 14 and received a second treatment at Day 14</population>
        <group_list>
          <group group_id="O1">
            <title>Permethrin Foam 4%; Permethrin Foam 4%</title>
            <description>First treatment with Permethrin Foam 4% with potential to re-treat with Permethrin Foam 4%, if necessary.&#xD;
Topical application, whole-body treatment</description>
          </group>
          <group group_id="O2">
            <title>Permethrin Foam 5%; Permethrin Foam 5%</title>
            <description>First treatment with Permethrin Foam 5% with potential to re-treat with Permethrin Foam 5%, if necessary.&#xD;
Topical application, whole-body treatment</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Foam; Permethrin Foam 4%</title>
            <description>First treatment with Vehicle with potential to re-treat with Permethrin Foam 4%, if necessary.&#xD;
Topical application, whole-body treatment</description>
          </group>
          <group group_id="O4">
            <title>Vehicle; Permethrin Foam 5%</title>
            <description>First treatment with Vehicle with potential to re-treat with Permethrin Foam 5%, if necessary.&#xD;
Topical application, whole-body treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Re-treated Subjects Designated as &quot;Treatment Success&quot;</title>
          <description>Each subject was designated as &quot;re-treatment success&quot; at Day 42 based upon the criteria in the protocol to which he/she was enrolled. In protocol v2.0, &quot;treatment success&quot; was defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear). In protocol v3.0, &quot;treatment success&quot; was defined as an &quot;eradication of infestation&quot;: a) no burrows, b) a reduction in the Signs/Symptoms, and c) no evidence of a live mite on microscopy.</description>
          <population>ITT subjects who did not improve at Day 14 and received a second treatment at Day 14</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6937</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Designated as &quot;Treatment Success&quot; Following One Treatment With an Active Dose</title>
        <description>The proportion of subjects designated as &quot;treatment success&quot; following one treatment versus two treatments.&#xD;
In protocol v2.0, &quot;treatment success&quot; was defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear). In protocol v3.0, &quot;treatment success&quot; was defined as an &quot;eradication of infestation&quot;: a) no burrows, b) a reduction in the Signs/Symptoms, and c) no evidence of a live mite on microscopy.&#xD;
Subjects originally assigned to vehicle treatment and re-treated on Day 14 with an active dose will be included with the single treatment group for this analysis.&#xD;
Subjects who did not improve at Day 14 were counted as failures at Day 28. Subjects who improved at Day 14 and received a second treatment in error were counted as failures at Day 28.</description>
        <time_frame>Day 28 and Day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Permethrin Foam 4% Two Active Treatments</title>
            <description>First treatment with Permethrin Foam 4%, second treatment with Permethrin Foam 4%.&#xD;
Topical application, whole-body treatment</description>
          </group>
          <group group_id="O2">
            <title>Permethrin Foam 5% Two Active Treatments</title>
            <description>First treatment with Permethrin Foam 5%, second treatment with Permethrin Foam 5%.&#xD;
Topical application, whole-body treatment</description>
          </group>
          <group group_id="O3">
            <title>Permethrin Foam 4% Single Active Treatment</title>
            <description>If the subject was improved at Day 14 and only received one treatment (Permethrin Foam, 4%), or if the subject received Vehicle Foam at Baseline, was not improved at Day 14, and received a single active (Permethrin Foam, 4%) treatment at Day 14.&#xD;
Topical application, whole-body treatment</description>
          </group>
          <group group_id="O4">
            <title>Permethrin Foam 5% Single Active Treatment</title>
            <description>If the subject was improved at Day 14 and only received one treatment (Permethrin Foam, 5%), or if the subject received Vehicle Foam at Baseline, was not improved at Day 14, and received a single active (Permethrin Foam, 5%) treatment at Day 14.&#xD;
Topical application, whole-body treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Designated as &quot;Treatment Success&quot; Following One Treatment With an Active Dose</title>
          <description>The proportion of subjects designated as &quot;treatment success&quot; following one treatment versus two treatments.&#xD;
In protocol v2.0, &quot;treatment success&quot; was defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear). In protocol v3.0, &quot;treatment success&quot; was defined as an &quot;eradication of infestation&quot;: a) no burrows, b) a reduction in the Signs/Symptoms, and c) no evidence of a live mite on microscopy.&#xD;
Subjects originally assigned to vehicle treatment and re-treated on Day 14 with an active dose will be included with the single treatment group for this analysis.&#xD;
Subjects who did not improve at Day 14 were counted as failures at Day 28. Subjects who improved at Day 14 and received a second treatment in error were counted as failures at Day 28.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1010</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0764</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Subjects randomized to Vehicle/Permethrin Foam, 5% or Vehicle/Permethrin Foam, 4% who received a second treatment are counted in the Permethrin Foam, 5% or Permethrin Foam, 4% and Vehicle treatment groups. For subjects randomized to Vehicle Foam on Day 1 who were re-treated at Day 14 (Visit 3), Adverse Events (AEs) were assigned to Vehicle Foam group if the event occurred before Day 14 (Visit 3) or to the active treatment group if the event took place after Day 14 (Visit 3).</desc>
      <group_list>
        <group group_id="E1">
          <title>Permethrin Foam 4%</title>
          <description>Treatment with Permethrin Foam 4%.&#xD;
Topical application, whole-body treatment</description>
        </group>
        <group group_id="E2">
          <title>Permethrin Foam 5%</title>
          <description>Treatment with Permethrin Foam 5%.&#xD;
Topical application, whole-body treatment</description>
        </group>
        <group group_id="E3">
          <title>Vehicle Foam</title>
          <description>Treatment with Vehicle Foam.&#xD;
Topical application, whole-body treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In the event said right to publish is exercised, the Investigator shall submit to Sponsor for review 60 days prior to any publication. In the event that Sponsor desires to take patent action, Investigator agrees to delay the publication an additional 60 days. Sponsor shall have the right to review and comment upon such publication. Notwithstanding the foregoing, no paper that incorporates Sponsor Confidential Information shall be submitted for publication without Sponsor's prior written consent.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Sciences Program Lead</name_or_title>
      <organization>Mylan Pharmaceuticals Pvt Ltd</organization>
      <email>prasannac.ganapathi@mylan.in</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

